Riding the wave of successes of ALK and ROS1 targeted therapy in non-small cell lung cancer (NSCLC), few clinical trials are testing these treatments in ALK and ROS1 positive BTCs population. The gene discussed is ALK; the disease is non-small cell lung carcinoma.